Business Wire

Thales Leads Innovative Digital Transformation of the Mauritius National Identity System

Share

The Mauritius Prime Minister's Office (PMO) has entrusted the consortium led by Thales, which includes the leading Mauritian-grown IT providerHarel Mallac Technologies (HMT), with a crucial step toward developing a comprehensive National ID system to improve citizen services and bolstering identity security. This partnership sets the foundations for the next generation digital journey of Mauritius, fully aligned with the country’s 2030 digital strategy.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240523106005/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

©Thales

This ambitious modernisation effort draws on Thales experience from 300 government projects worldwide, and ensures that field-proven technology can be associated for timely delivery and reliable project execution. It is a long-term partnership providing consistent and expert support in all key components of the identity scheme, from citizen enrolment to physical and digital ID issuance. This end-to-end approach effectively meets future evolutions as well as potential identity threats.

As part of the 10-year contract Thales is providing a powerful and modular Identity Management System to securely issue cutting-edge eID cards and its mobile companion, the Digital ID Wallet. The solution assures comprehensive trust and privacy in daily interactions between public entities and individuals. The user experience is at the core of this modernisation drive, illustrated by the wider range of new functionalities and services it brings to citizens.

The citizen’s journey starts with a frictionless enrolment process, which can be initiated online from the comfort of home to save citizens time when visiting the enrolment centre. Once enrolled, the holder will receive a new eID card which relies on the latest Thales embedded software and advanced security features, including high resolution colour photo1, to effectively combat forgery and identity theft. For more convenience, self-service kiosks will be installed at dedicated spots to enable users to update their ID cards’ information (with new address, etc) and manage the PIN code associated with the digital certificates stored in their card.

Citizens can also activate their Digital ID Wallet, a secure mobile application where they can securely store and share digital identity documents. The wallet will initially include digital versions of the identity card and will subsequently contain other official documents such as birth and marriage certificates. These may then be shared both online and in-person. Citizens will also be able to digitally sign documents with a one-time certificate as well as log in to online government services by using their digital wallet. For service providers (public administrations, banks, retailers, universities, etc…) it will be a simpler and more secure way to verify identities. Citizens’ control over their personal data is guaranteed thanks to stringent data privacy and consent management mechanisms.

Mauritius identity cards production will benefit from Thales factories’ sustainability action plan, which aims to reduce the carbon footprint by utilising 100% renewable electricity, optimising energy consumption and minimising waste. As a complement to this approach, the Mauritius project is part of Thales' offsetting program which supports sustainable initiatives2 worldwide (selected in collaboration with Climate Impact Partner) by offsetting the carbon emissions from all its travel and ID solutions.

During the official launching on 26th February 2024 of the national ID card at the Sir Harilal Vaghjee Memorial Hall, Government Centre, Port Louis, it was stated that:
“The purpose of modernising the present system with sophisticated and next generation technology is to enable new services while increasing citizen security and convenience. The next-generation ID system will lay the foundation for supporting the country's digital transformation, benefiting all stakeholders and fostering economic growth.”

“With this implementation, blending ID cards and digital identity, Mauritius fully leverages the best of both worlds, offering the optimal combination of security and ease,” says Youzec Kurp, VP Identity and Biometrics Solutions at Thales. “The new Mauritius ID system stands as one of the most advanced and marks the first implementation of a fully interoperable Digital ID Wallet in Africa, adhering to international ISO standards. This positions Mauritius amongst the pioneer countries in identity solutions worldwide.”

1 The new e-document incorporates latest generation of embedded software together with advanced physical features such as Thales Colour Laser Shield technology (high resolution colour portrait) ensuring state-of-the-art protection against counterfeiting for both blank and personalised documents, True Vision (high resolution true-colour UV picture), transparent window element with the holders’ ghost image, and Secure Surface 3D tactile features combining movement and light reflection.
2 Example of supported projects in 2023: Vichada Afforestation in Colombia, Aqua Clara Water Filters in Kenya, Renewable Energy Portfolio worldwide.

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies specialized in three business domains: Defence & Security, Aeronautics & Space, and Cybersecurity & Digital identity.

It develops products and solutions that help make the world safer, greener and more inclusive.

The Group invests close to €4 billion a year in Research & Development, particularly in key innovation areas such as AI, cybersecurity, quantum technologies, cloud technologies and 6G.

Thales has close to 81,000* employees in 68 countries. In 2023, the Group generated sales of €18.4 billion.

* These figures exclude the ground transportation business, which is being divested.

PLEASE VISIT

Thales Group
Digital Identity & Security

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PRESS CONTACT

Thales, Media Relations
Digital Identity and Security
Vanessa Viala
+33 (0)6 07 34 00 34
vanessa.viala@thalesgroup.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia23.6.2024 04:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today presented positive results from its Phase 2b, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and efficacy of mezagitamab (TAK-079) in patients with persistent or chronic primary immune thrombocytopenia (ITP), a rare immune-mediated bleeding disorder. ITP is characterized by the accelerated destruction of platelets in blood, resulting in a decreased platelet count and an increase of bleeding that can be debilitating. These data (Abstract #LB 01.1) were presented at the oral Late-Breakthrough Session at the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Bangkok, Thailand. Takeda plans to initiate a global Phase 3 trial of mezagitamab in patients with ITP in the second half of FY2024. The TAK-079-1004 trial (NCT04278924) evaluated three different doses of subcutaneous mezagitamab (100mg, 300mg and 600mg) versus placebo, given once weekly for eight weeks in patients with chronic or

PMC Biogenix Announces Expansion and Restructure21.6.2024 23:00:00 CEST | Press release

PMC Biogenix, the leading sustainable producer of specialty fatty amides and high-value biobased products, announces the construction and expansion of its new Armoslip® facility in Gyeongju, South Korea allowing for a production capacity increase of 50%. Construction will begin late 2024 with new supply available by mid-2026. “We are excited to announce plans to build a new facility in Gyeongju. This investment will allow us to significantly increase production capacity to meet growing customer demand for our Armoslip products,” said Debtosh Chakrabarti, President, PMC Group N.A., Inc. Adding, “This project solidifies our commitment as the industry leader, delivering products and solutions to our customers, as well as to the local Gyeongju community. We appreciate the continued support of the Gyeongju, South Korea local government, community, and our customers.” As part of PMC’s ongoing commitment of ensuring long-term sustainability and success of the Biogenix business world-wide, a c

Esri Technology Used By ALS Therapy Development Institute to Map Clinical Trials21.6.2024 22:58:00 CEST | Press release

The ALS Therapy Development Institute (ALS TDI), a nonprofit biotech dedicated to ending amyotrophic lateral sclerosis (ALS), has used mapping technology from Esri, the global leader in location intelligence, to develop the ALS Trial Navigator. The new tool is designed to simplify and streamline the process by which people with ALS and their caretakers learn about current ALS studies. With the ALS Trial Navigator users can now explore an interactive map to find locations where applicable clinical trials are taking place. They can also receive a customized map based on their preferences and status of their ALS. "ALS Trial Navigator helps people living with ALS, those that might face it in the future, and researchers looking to enroll trials by educating the community and providing information about current studies all around the world," said Dr. Nadia Sethi, ALS TDI's director of community engagement, who oversaw the Navigator's design and creation. Once a person is diagnosed with ALS,

Lifezone Metals Announces Voting Results from its 2024 Annual General Meeting21.6.2024 22:30:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) announces the results of voting by shareholders at its 2024 Annual General Meeting (the “AGM”) held today in the Isle of Man. The ordinary resolutions below were passed by shareholders, with voting results as follows: Ordinary Resolutions For % For Against % Against Abstain % Abstain To receive the Company’s accounts for the financial year ended December 31, 2023 60,456,134 100.00% 0 0.00% 264 0.00% To re-elect John Dowd as a Class I Director of the Company 60,375,930 99.87% 79,177 0.13% 1,291 0.00% To re-elect Govind Friedland as a Class I Director of the Company 59,713,208 98.77% 79,319 0.13% 663,871 1.10% To re-elect Ambassador Mwanaidi Maajar as a Class I Director of the Company 60,314,469 99.77% 81,886 0.14% 60,043 0.10% A total of 60,456,398 or 75.57% of Lifezone Metals Ordinary Shares outstanding were represented at the AGM. If you would like to sign up for Lifezone Metals news alerts, please register here. About Lifezone Metals At Lifezone Me

Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer21.6.2024 22:00:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved FRUZAQLA (fruquintinib) as a monotherapy indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents, and who have progressed on or are intolerant to treatment with either trifluridine-tipiracil or regorafenib. The decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on April 25, 2024, and approval by the U.S. Food and Drug Administration (FDA) for adults with mCRC who have been previously treated with oxaliplatin- and irinotecan-based regimens on November 8, 2023.1,2 “People living with metastatic colorectal cancer face numerous difficulties, stemming both from their illness and the adverse effects of therapies. Given the complex nature of the d

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye